We are live on ! Find out more
ITCI

Intra-Cellular Therapies Inc.
ITCI

Delisted

ITCI was delisted on the 1st of April, 2025.

Back to rankings

274 hedge funds and large institutions have $3.85B invested in Intra-Cellular Therapies Inc. in 2022 Q3 according to their latest regulatory filings, with 43 funds opening new positions, 103 increasing their positions, 86 reducing their positions, and 35 closing their positions.

New
Increased
Maintained
Reduced
Closed

23% more first-time investments, than exits

New positions opened: 43 | Existing positions closed: 35

20% more repeat investments, than reductions

Existing positions increased: 103 | Existing positions reduced: 86

13% more call options, than puts

Call options by funds: $21.3M | Put options by funds: $18.9M

3% more funds holding

Funds holding: 266 → 274 (+8)

16% less capital invested

Capital invested by funds: $4.57B → $3.85B (-$727M)

36% less funds holding in top 10

Funds holding in top 10: 11 → 7 (-4)

Holders
274
Holders Change
+8
Holders Change %
+3.01%
% of All Funds
4.72%
Holding in Top 10
7
Holding in Top 10 Change
-4
Holding in Top 10 Change %
-36.36%
% of All Funds
0.12%
New
43
Increased
103
Reduced
86
Closed
35
Calls
$21.3M
Puts
$18.9M
Net Calls
+$2.43M
Net Calls Change
-$6.17M

Top Buyers

1
GKIM
GW&K Investment Management
Massachusetts
+$46.1M
2
Invesco
Invesco
Georgia
+$45.3M
3
Millennium Management
Millennium Management
New York
+$42M
4
Wellington Management Group
Wellington Management Group
Massachusetts
+$36.3M
5
Point72 Asset Management
Point72 Asset Management
Connecticut
+$34.3M

Top Sellers

1
Victory Capital Management
Victory Capital Management
Texas
-$43.9M
2
Adage Capital Partners
Adage Capital Partners
Massachusetts
-$36.5M
3
DCM
Driehaus Capital Management
Illinois
-$29.4M
4
SCM
Suvretta Capital Management
New York
-$25.4M
5
CAM
Cormorant Asset Management
Massachusetts
-$15.7M
Name Holding Trade Value Shares
Change 		Change in
Stake
SO
126
STRS Ohio
Ohio
$1.44M – – –
OAM
127
Oppenheimer Asset Management
New York
$1.42M +$620K +11,877 +64%
JIP
128
Jaffetilchin Investment Partners
Florida
$1.41M -$24.4K -467 -2%
BMSSC
129
B. Metzler seel. Sohn & Co
Germany
$1.33M +$25K +478 +2%
State Board of Administration of Florida Retirement System
130
State Board of Administration of Florida Retirement System
Florida
$1.32M – – –
VAFP
131
Vahanian & Associates Financial Planning
New York
$1.25M -$569K -10,900 -29%
BCI
132
Brinker Capital Investments
Pennsylvania
$1.25M +$1.4M +26,766 New
Ensign Peak Advisors
133
Ensign Peak Advisors
Utah
$1.13M -$5.28M -101,153 -81%
MC
134
Miramar Capital
Illinois
$1.1M -$355K -6,800 -24%
TRSOTSOK
135
Teachers Retirement System of the State of Kentucky
Kentucky
$1.1M +$1.23M +23,594 New
VI
136
Versor Investments
New York
$1.09M +$415K +7,951 +51%
ASRS
137
Arizona State Retirement System
Arizona
$1.07M +$28.7K +550 +2%
EAM
138
Erste Asset Management
Austria
$1.06M – – –
MFS
139
Mirabella Financial Services
United Kingdom
$1.06M +$1.19M +22,718 New
SG Americas Securities
140
SG Americas Securities
New York
$1.03M +$417K +7,987 +56%
BPC
141
Banque Pictet & Cie
Switzerland
$980K +$1.1M +21,068 New
AI
142
Atom Investors
Texas
$978K -$543K -10,404 -33%
Natixis Advisors
143
Natixis Advisors
Massachusetts
$977K +$110K +2,099 +11%
EGM
144
Engineers Gate Manager
New York
$974K -$1.03M -19,671 -48%
AQR Capital Management
145
AQR Capital Management
Connecticut
$947K -$141K -2,702 -12%
WMSA
146
Weiss Multi-Strategy Advisers
New York
$907K -$31.1K -595 -3%
PAM
147
Panagora Asset Management
Massachusetts
$900K +$1.1K +21 +0.1%
ProShare Advisors
148
ProShare Advisors
Maryland
$840K +$20.2K +387 +2%
Squarepoint
149
Squarepoint
New York
$810K +$909K +17,410 New
Jennison Associates
150
Jennison Associates
New York
$805K +$217K +4,154 +32%
4 5
6
7 8

ITCI Hedge Fund Activity: Q3 2022 in Review

274 of the 5,805 institutional investors tracked by Wall St. Rank reported a position in Intra-Cellular Therapies Inc. (ITCI) for Q3 2022, worth a combined $3.85B — down 16% from $4.57B a quarter earlier.

Buyers outnumbered sellers: 43 funds opened new ITCI positions and 35 closed out — a net gain of 8 holders — while 103 added to existing stakes and 86 trimmed.

The largest buyer was GW&K Investment Management, adding an estimated $46.1M. The largest seller was Victory Capital Management, cutting an estimated $43.9M.

  • 274 institutional investors held Intra-Cellular Therapies Inc. (ITCI) as of Q3 2022, up from 266 in Q2 2022.
  • Funds reported $3.85B of Intra-Cellular Therapies Inc. stock for Q3 2022, down 16% quarter-over-quarter.
  • 43 funds opened new Intra-Cellular Therapies Inc. positions in Q3 2022 and 35 closed out, a net change of +8 holders.
  • The largest Intra-Cellular Therapies Inc. buyer in Q3 2022 was GW&K Investment Management, an estimated $46.1M added.
  • The largest Intra-Cellular Therapies Inc. seller in Q3 2022 was Victory Capital Management, an estimated $43.9M sold.

Based on aggregated 13F filings for Q3 2022.